期刊文献+

OATP1B1基因多态性对匹伐他汀钙片在中国汉族健康受试者体内的药代动力学影响 被引量:4

Effects of organic anion transporting polypeptide 1B1 polymorphism on the pharmacokinetics of pitavastatin calcium tablet in healthy subjects of Chinese Han population
下载PDF
导出
摘要 目的:研究有机阴离子转运多肽OATP1B1基因多态性对匹伐他汀钙片在中国汉族健康受试者体内的药代动力学影响。方法:用PCR-RFLP对筛选出的36名合格受试者进行OATPlBl A388G、OATPlBl T521C基因分型,受试者单剂量口服匹伐他汀钙片2 mg,用HPLC-MS-MS法测定血浆匹伐他汀钙片浓度。结果:匹伐他汀钙片药代动力学参数显示,与388AA型相比,388AG型AUC0-10增加26%,t1/2增加30%;与521TT型相比,521TC型AUC0-10增加23.6%,CL/F降低20.8%。可能由于突变例数太少,导致OATP1B1 A388G和OATP1B1 T521C突变组和野生组各药代动力学参数(t1/2、tmax、Cmax、AUC0-t、AUC0-inf、CL/F、Vd/F)之间差异无明显统计学意义。结论:OATP1B1基因多态性可能对中国汉族人群中匹伐他汀钙片代谢无影响。 Objective: To investigate the influence of organic anion transporting polypeptide 1B1 polymorphism on the pharmacokinetics of pitavastatin calcium tablets in healthy subjects of Chinese Han population.Methods: Apply PCR-RFLP to measure the genetypes of OATP1B1 A388G,OATPlBl T521C in 36 healthy subjects.Each was given a single oral dose of 2 mg pitavastatin calcium tablet.The plasma concentrations of pitavastatin calcium tablet were measured by HPLC-MS-MS.Results: The AUC0-10 of pitavastatin calcium tablet significantly increased 26%,and t1/2 increased 30% in subjects expressing the 388AG genotype compared with 388AA subjects.The AUC0-10 of pitavastatin calcium tablets increased 23.6%,and CL/F decreased 20.8% in subjects expressing the 521TC genotype compared with 521TT subjects.The parameters(t1/2,tmax,Cmax,AUC0-t,AUC0-inf,CL/F,Vd / F) had no significant statistical difference in mutate group and wild group of OATP1B1 A388G and OATP1B1 T521C.Conclusion: The OATP1B1 polymorphism may have no effect on the pharmacokinetics of pitavastatin calcium tablet in Chinese Han population.
出处 《中国药物应用与监测》 CAS 2011年第3期147-150,共4页 Chinese Journal of Drug Application and Monitoring
关键词 有机阴离子转运多肽1B1 匹伐他汀钙片 基因多态性 药代动力学 Organic anion transporting polypeptide 1B1 Pitavastatin calcium tablet Polymorphism Pharmacokinetics
  • 相关文献

参考文献3

二级参考文献52

  • 1Mukhtar RY, Reid J, Reckless JP. Pitavastatin[ J]. Int J Clin Pract, 2005 ;59:239 -252.
  • 2Reinoso RF, S Navarro A ,Garcia MJ, et al. Preclinical pharmacokinetics of statins [ J ]. Methods Find Exp Clin Pharmacol, 2002 ; 24 : 593 -613.
  • 3Garcia MJ, Reinoso RF, Navarro AS,et al. Clinical pharmacokinetics of statins [ J ]. Methods Find Exp Clin Pharmacol, 2003 ; 25 : 457 - 481.
  • 4Fujino H, Kojina J, Yamada Y ,et al. Studies on the metabolic fate of NK- 104, a new inhibitor of HMG- CoA reductase (4) : Interspecies variation in laboratory animals and humans[ J]. Xenobiol Metab Dispos, 1999; 14:79-81.
  • 5Chong PH, Seeger JD, Franklin C. Clinically relevant differences between the statins: Implications for therapeutic selection [ J ]. Am J Med,2001 ; 111 : 390 -400.
  • 6Wierzbicki AS, Poston R, Ferru A. The lipid and nonlipid effects of statins[ J]. Pharmacol Ther,2003 ; 99 : 95 - 112.
  • 7Fujino H, Yamada I, Kojima J ,et al. Studies on the metabolic fate of NK - 104, a new inhibitor HMG - CoA reductase (5) :In vitro metabolism and plasma protein binding in animals and human [ J ]. Xeno Metab Disp, 1999 ; 14:415 - 424.
  • 8Kimata H, Fujino H, Koide T,et al. Studies on the metabolic fate of NK - 104, a new inhibitor of HMG - CoA reductase ( 1 ) :Absorption, distribution, metabolism and excretion in rats [ J ]. Xenobiol Metab Dispos,1998; 13 : 484 -498.
  • 9Fujino H, Morikawa S, Kanda H,et al. Studies on the metabolic fate of NK - 104, a new inhibitor of HMG - CoA reductase (3) : Foeto - pla-cental transfer and mammary excretion after oral administration in rats [J] . Xenobiol Metab Dispos, 1998;13 : 508 -515.
  • 10Masaru H, Kazuya M, Yoshihisa S, et al. Contribution of OATP2 ( OATP1 B1 ) and OATP8 ( OATP1 B3 ) tothe hepatic uptake of pitavastatin in humans[J]. J Pharmacol Exp,2004 ;311 : 139 - 146.

共引文献34

同被引文献38

  • 1叶平.2012他汀类药物安全性再认识[J].中国医学前沿杂志(电子版),2012,4(8):1-4. 被引量:13
  • 2仝其广,胡大一.他汀类药物的安全性问题[J].中国实用内科杂志,2007,27(9):655-657. 被引量:64
  • 3牛瑞仙,徐秀丽.药源性横纹肌溶解症及其诊疗进展[J].社区医学杂志,2010,7(5):309-310.
  • 4Lin-yong XU,Yi-jing HE,Wei ZHANG,Sheng Deng,Qing LI,Wei-xia ZHANG,Zhao-qian LIU,Dan WANG,Yuan-fei HUANG,Hong-hao ZHOU,Zhen-qiu SUN.Organic anion transporting polypeptide-1B1 haplotypes in Chinese patients[J].Acta Pharmacologica Sinica,2007,28(10):1693-1697. 被引量:18
  • 5American Diabetes Association.Standards of medical care in dia betesd-2014[J].Diabetes Care,2014,37 (Suppl1):S14-80.
  • 6Baek SD,Jang SJ,Park SE,et al.Fatal rhabdomyolysis in a patient with liver cirrhosis after switching from simvastatin to fluvastatin[J].J Korean Med Sci,2011,6 (12):1634-1637.
  • 7Filippatos TD,Elisaf MS.Fenofibrate plus simvastin (fixed-dose combination) for the treatment of dyslipidaemia[J].Exp Opin Pharmacother,2011,12 (12):1945-1958.
  • 8Ginberg HN.The ACCORD(Action to control Cardiovascular Risk in Diabetes)Lipid trial:what we learn from subgroup analyses[J].Diabetes Care,2011,34(Suppl2):S107-108.
  • 9Kashani A,Phillips CO,Foody JM.Risks associated with statin therapy:a systematic overview of randomized clinical trials[J].Circulation,2006,114(25):2788-2797.
  • 10Pastemak RC,Smith SC Jr,Bairey-Merz CN,et al.ACC/AHA/ NHLBI clinical advisory on the use and safety of statins[J].J An Coll Cardiol,2002,40 (3):567-572.

引证文献4

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部